There are several quality risk management trends in the pharmaceutical industry that have emerged in recent years. These trends aim to improve the overall quality and safety of pharmaceutical products and processes. Some of the key trends include: 1. Implementation of Quality by Design (QbD): QbD is an approach that focuses on building quality…
As a life science sector audit and inspection are common terms in pharmaceutical industry. Here we going to mention a list of criteria of maintaining audit and inspection readiness at all times in pharma industry. 1. Clear Communication Channel Manufacturing and quality teams should establish clear communication channels. Regular meetings and discussions enable both…
pH and pKa are two important concepts in chemistry that are often confused. pH pKa The relationship between pH and pKa pH = pKa + log(A-/HA) Where, Is pKa the same as pH? It is important to remember that when the pH equals to pKa value, the proportions of conjugate base…
“In many organization, politics are allowed to influence the CAPAs simply because there are too many people involved in the approval process—approval to actually open a CAPA, or approval to finish one. Very often there are too many people, or the wrong people, in the approval process. I’ve seen real problems get swept under…
Non-sink conditions refer to situations where the concentration of the drug substance in the dissolution medium is not significantly lower than its solubility. While sink conditions are commonly preferred in dissolution testing to ensure rapid and complete drug dissolution, there are certain instances where non-sink conditions can be useful. Here are a few examples:…
Sink conditions refer to a state in which the dissolution medium has sufficient volume to ensure the drug dissolves rapidly without reaching saturation throughout the duration of the test. Sink conditions = V/Vsat ≥ 3 Where, Volume of Dissolution Medium The volume of the dissolution medium should be at least 3-10 times the saturation…
In Europe, The EMA coordinates the assessment of reports of product quality defects of centrally authorized medicines. Medicinal products with a quality defect are not of the correct quality as defined by their marketing authorization. It is important to report these defects in a timely manner because sometimes it is necessary to implement…
Corrective and Preventive Action (CAPA) was first formally introduced by the U.S. Food and Drug Administration (FDA) in 2006 as a component of the Quality Systems Guidance. This guidance would go on to form the basis of the ICH Q10. Since then, it’s found its way into the EU GMP Guide, laying out the…
